Vitamin market remains depressed as prices continue to weaken
Persistent price weakness continues across key vitamins, with sluggish demand and ample supply dominating market sentiment. Despite attempts to raise prices, sellers face resistance, and Q4 remains largely uncovered. Recent shifts in availability and regional dynamics add to market uncertainty.
In partnership with Feed Additive Prices
Vitamin E 50%
The overall trend for vitamin E has remained sluggish for several months, with certain weeks experiencing more significant price reductions than others. Recently, the decline has been particularly pronounced outside the USA, although USA prices are now declining more as well. End users report that material availability from suppliers remains adequate, despite constant attempts to increase prices. While the third quarter is predominantly secured, the fourth quarter still presents many open opportunities.
Vitamin A 1000
Vitamin A continues to be weak and has reached very low price levels. With the recently lifted force majeure from one of the western manufacturers, new supply coming from China, and overall reduced demand, the market expects to remain in this bearish trend for now. Even though manufacturers are not pleased at all with the currently low price level. Q3 is mostly contracted, although some buyers have a spot buying strategy still. Q4 is mostly uncovered.
Vitamin D3 500
The current market exhibits a considerable price variation, with suppliers raising prices and curtailing offers while lower-priced materials remain available from immediate stock. This dynamic has created a diverse range of prices across different regions. While the third quarter is largely contracted, the fourth quarter remains mostly open as buyers are hesitant to commit fully.
D-Calpan
The decline in d-calpan prices remains evident, showing a slight further decrease. However, the pace of this decline has slowed. Ample supply and mounting sales pressure from key suppliers are noticeable across all major regions. Q3 remains partly uncontracted still, a cautious wait-and-see approach prevails among stakeholders.
Vitamin B3
Especially from Chinese sources, there is a strong sales pressure, and prices continue to weaken for vitamin B3. Despite already really low market prices, the market looks weak and oversupplied in all major regions. Buyers remain on the sidelines and sellers are keen to do business. Q3 is mostly contracted, but Q4 is still open in most cases.
